Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CDC42 | P60953 | 1/20 | 0.46 |
| ▸ | RAC1 | P63000 | 1/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2975910 | 1.00 | CYP1A2 (0.52) | CYP1A2CYP2A6ABCB11PTGS2AKR1C3 | |
| SCHEMBL22393854 | 0.86 | ABCB11 (0.45) | CYP1A2CYP2A6ABCB11PTGS2AKR1C3 | |
| SCHEMBL22313388 | 0.83 | ABCB11 (0.50) | CYP1A2CYP2A6ABCB11PTGS2AKR1C3 | |
| SCHEMBL15086617 | 0.82 | CYP1A2 (0.60) | CYP1A2CYP2A6ABCB11PTGS2AKR1C3 | |
| SCHEMBL22313717 | 0.82 | ABCB11 (0.49) | CYP1A2CYP2A6ABCB11PTGS2AKR1C3 | |
| SCHEMBL25092664 | 0.81 | CYP17A1 (0.40) | GAAALOX15LMNAMAPTCYP2C9 | |
| SCHEMBL1494382 | 0.81 | THRB (0.52) | MEN1ALDH1A1GAAKMT2AMAPT | |
| SCHEMBL8297978 | 0.81 | TRPA1 (0.55) | RAB9AMEN1ALDH1A1GAAALOX15 | |
| SCHEMBL25092650 | 0.80 | AKR1C3 (0.39) | AKR1C3AKR1C2RAB9AGAALMNA | |
| SCHEMBL2960747 | 0.80 | BCHE (0.47) | CYP1A2CYP2A6ABCB11PTGS2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230059865-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230025130-A1 | METHODS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11326165-B1 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11162101-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-11129829-B2 | Methods for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11091475-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210171519-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-11021708-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11008572-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200390765-A1 | METHODS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200277289-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-09-03 | — | — | US | disclosed |
| US-20200247799-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-08-06 | — | — | US | disclosed |
| EP-3689863-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| US-20200224199-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11129829-B2 | Methods for modulating splicing | RBM17, SNRPE, SNRPB2 | CYP1A2 4679/4885CYP2A6 4602/4885ABCB11 4807/4885 |
| US-11326165-B1 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | CYP1A2 4537/4885CYP2A6 4461/4885ABCB11 4816/4885 |
| US-11021708-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | CYP1A2 4537/4885CYP2A6 4461/4885ABCB11 4816/4885 |
| US-20230025130-A1 | METHODS FOR MODULATING SPLICING | RBM17, SNRPE, SNRPB2 | CYP1A2 4679/4885CYP2A6 4602/4885ABCB11 4807/4885 |
| US-20210171519-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | CYP1A2 4537/4885CYP2A6 4461/4885ABCB11 4816/4885 |
| US-20200247799-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | CYP1A2 4537/4885CYP2A6 4461/4885ABCB11 4816/4885 |
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | CYP1A2 4537/4885CYP2A6 4461/4885ABCB11 4816/4885 |
| US-11008572-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | CYP1A2 4537/4885CYP2A6 4461/4885ABCB11 4816/4885 |
| US-11162101-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | CYP1A2 4537/4885CYP2A6 4461/4885ABCB11 4816/4885 |
| US-11091475-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | CYP1A2 4537/4885CYP2A6 4461/4885ABCB11 4816/4885 |
| US-20200390765-A1 | METHODS FOR MODULATING SPLICING | RBM17, SNRPE, SNRPB2 | CYP1A2 4679/4885CYP2A6 4602/4885ABCB11 4807/4885 |
| US-20200277289-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | CYP1A2 4537/4885CYP2A6 4461/4885ABCB11 4816/4885 |
| US-20230059865-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | CYP1A2 4537/4885CYP2A6 4461/4885ABCB11 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.